***Commonwealth of Massachusetts***

***Executive Office of Health and Human Services***

***Office of Medicaid***

[*www.mass.gov/masshealth*](http://www.mass.gov/masshealth)

MassHealth

Managed Care Entity Bulletin 17

July 2019

**TO**: Managed Care Entities

**FROM**: Daniel Tsai, Assistant Secretary for MassHealth [Signature of Daniel Tsai]

**RE: Prior Authorization and Utilization Management for Suboxone® (buprenorphine/naloxone)**

# Background

To facilitate the provision of medically necessary medication to treat substance use disorders, EOHHS is establishing the following requirements effective immediately.

# Utilization Management including Prior Authorization for Suboxone® (buprenorphine/naloxone)

MassHealth Managed Care Entities (MCEs), including Managed Care Organizations (MCOs), Accountable Care Partnership Plans (ACPPs), One Care plans, Senior Care Options (SCOs), and the Massachusetts Behavioral Health Partnership (MBHP) must provide access to at least one buprenorphine/naloxone treatment at Suboxone® equivalent doses of 24 mg/day or less without prior authorization.

While MCEs may continue to impose quantity limits on buprenorphine/naloxone treatments, any such quantity limits must accommodate this rule, regardless of dosage strength. Therefore, if an MCE imposes quantity limits, the MCE must still allow for up to a total daily dose equal to or less than 24 mg without prior authorization.

# MassHealth Website

This bulletin is available on the MassHealth website at [www.mass.gov/masshealth-provider-bulletins](http://www.mass.gov/masshealth-provider-bulletins).

To sign up to receive email alerts when MassHealth issues new bulletins and transmittal letters, send a blank email to join-masshealth-provider-pubs@listserv.state.ma.us. No text in the body or subject line is needed.

# Questions

If you have any questions about the information in this bulletin, please contact the MassHealth Customer Service Center at (800) 841-2900, email your inquiry to providersupport@mahealth.net, or fax your inquiry to (617) 988‑8974.